John Soucie

List of Publications by Year in descending order

67 papers	5,367 citations	117453 34 h-index	102304 66 g-index
68 all docs	68 docs citations	68 times ranked	2987 citing authors

#	Article	IF	Citations
1	Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia. New England Journal of Medicine, 2007, 357, 535-544.	13.9	1,681
2	Range of motion measurements: reference values and a database for comparison studies. Haemophilia, 2011, 17, 500-507.	1.0	293
3	Occurrence of hemophilia in the United States. , 1998, 59, 288-294.		288
4	Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood, 2000, 96, 437-42.	0.6	266
5	Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood, 2004, 103, 2467-2473.	0.6	225
6	Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Preventionâ€™s (CDC) Universal Data Collection (UDC) project. Haemophilia, 2009, 15, 1281-1290.	1.0	127
7	Impact of inhibitors on hemophilia a mortality in the <scp>U</scp>nited <scp>S</scp>tates. American Journal of Hematology, 2015, 90, 400-405.	2.0	127
8	Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. Blood, 2017, 129, 2368-2374.	0.6	121
9	Prevalence and risk factors for heart disease among males with hemophilia. American Journal of Hematology, 2005, 79, 36-42.	2.0	115
10	F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. Haemophilia, 2012, 18, 375-382.	1.0	109
11	Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States. British Journal of Haematology, 2011, 152, 211-216.	1.2	98
12	Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia. Haemophilia, 2001, 7, 198-206.	1.0	96
13	Men with severe hemophilia in the United States: birth cohort analysis of a large national database. Blood, 2016, 127, 3073-3081.	0.6	93
14	Validation of Nijmegenâ€“Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. Journal of Thrombosis and Haemostasis, 2012, 10, 1055-1061.	1.9	92
15	Changes in the occurrence of and risk factors for hemophilia-associated intracranial hemorrhage. American Journal of Hematology, 2001, 68, 37-42.	2.0	89
16	Renal disease among males with haemophilia. Haemophilia, 2003, 9, 703-710.	1.0	84
17	Surveillance of female patients with inherited bleeding disorders in United States Haemophilia Treatment Centres. Haemophilia, 2011, 17, 6-13.	1.0	71
18	Healthcare expenditures for males with haemophilia and employerâ€sponsored insurance in the United States, 2008. Haemophilia, 2012, 18, 268-275.	1.0	69

#	Article	IF	Citations
19	The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B. Blood Advances, 2018, 2, 2136-2144.	2.5	69
20	Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US). Haemophilia, 2011, 17, 597-604.	1.0	63
21	Health care expenditures for Medicaidâ€covered males with haemophilia in the United States, 2008. Haemophilia, 2012, 18, 276-283.	1.0	63
22	In nonâ€severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a caseâ€“control study. Journal of Thrombosis and Haemostasis, 2010, 8, 2224-2231.	1.9	60
23	Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. Journal of Thrombosis and Haemostasis, 2006, 4, 2576-2581.	1.9	56
24	Pediatric Hemophilia: A Review. Seminars in Thrombosis and Hemostasis, 2011, 37, 737-744.	1.5	56
25	Comparison of clotâ€based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. Journal of Thrombosis and Haemostasis, 2013, 11, 1300-1309.	1.9	56
26	Prevalent inhibitors in haemophilia <scp>B</scp> subjects enrolled in the <scp>U</scp>niversal <scp>D</scp>ata <scp>C</scp>ollection database. Haemophilia, 2014, 20, 25-31.	1.0	56
27	Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System. Haemophilia, 2017, 23, 207-214.	1.0	56
28	The Universal Data Collection Surveillance System for Rare Bleeding Disorders. American Journal of Preventive Medicine, 2010, 38, S475-S481.	1.6	54
29	NHFâ€McMaster Guideline on Care Models for Haemophilia Management. Haemophilia, 2016, 22, 6-16.	1.0	50
30	The longitudinal effect of body adiposity on joint mobility in young males with Haemophilia A. Haemophilia, 2011, 17, 196-203.	1.0	47
31	Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database. Haemophilia, 2012, 18, e260-5.	1.0	45
32	Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres. Haemophilia, 2020, 26, 487-493.	1.0	41
33	Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasmaâ€derived factor concentrates in the era of nucleic acid test screening. Transfusion, 2013, 53, 1217-1225.	0.8	40
34	A study of prospective surveillance for inhibitors among persons with haemophilia in the United States. Haemophilia, 2014, 20, 230-237.	1.0	37
35	Physical Functioning in Boys with Hemophilia in the U.S.. American Journal of Preventive Medicine, 2011, 41, S360-S368.	1.6	35
36	Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease. Haemophilia, 2009, 15, 918-925.	1.0	30

#	Article	IF	Citations
37	Public health surveillance and data collection: general principles and impact on hemophilia care. Hematology, 2012, 17, s144-s146.	0.7	28
38	The effects of joint disease, inhibitors and other complications on healthâ€related quality of life among males with severe haemophilia A in the United States. Haemophilia, 2017, 23, e287-e293.	1.0	28
39	Evaluation of CDCâ€™s Hemophilia Surveillance Program â€" Universal Data Collection (1998â€"2011) and Community Counts (2011â€"2019), United States. MMWR Surveillance Summaries, 2020, 69, 1-18.	18.6	26
40	Burden of Disease Resulting from Hemophilia in the U.S.. American Journal of Preventive Medicine, 2010, 38, S482-S488.	1.6	25
41	Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation. Transfusion, 2004, 44, 1179-1185.	0.8	24
42	Septic arthritis in males with haemophilia. Haemophilia, 2008, 14, 494-503.	1.0	24
43	The effect of secondary prophylaxis versus episodic treatment on the range of motion of target joints in patients with haemophilia. British Journal of Haematology, 2013, 161, 424-433.	1.2	21
44	Prevalence of malignancies among U.S. male patients with haemophilia: a review of the Haemophilia Surveillance System. Haemophilia, 2012, 18, 532-539.	1.0	20
45	Care models in the management of haemophilia: a systematic review. Haemophilia, 2016, 22, 31-40.	1.0	20
46	Hepatitis B vaccination is effective by subcutaneous route in children with bleeding disorders: a universal data collection database analysis. Haemophilia, 2015, 21, e39-43.	1.0	15
47	Relevance of Abusive Head Trauma to Intracranial Hemorrhages and Bleeding Disorders. Pediatrics, 2018, 141, e20173485.	1.0	15
48	Populationâ€based surveillance of haemophilia and patient outcomes in Indiana using multiple data sources. Haemophilia, 2019, 25, 456-462.	1.0	15
49	Prevalence of clinical hip abnormalities in haemophilia A and B: an analysis of the <scp>UDC</scp> database. Haemophilia, 2013, 19, 426-431.	1.0	14
50	Knowledge and Therapeutic Gaps. American Journal of Preventive Medicine, 2011, 41, S324-S331.	1.6	13
51	Occurrence rates of von Willebrand disease among people receiving care in specialized treatment centres in the United States. Haemophilia, 2021, 27, 445-453.	1.0	13
52	Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A. Haemophilia, 2013, 19, 595-601.	1.0	12
53	Association of overweight and obesity with the use of self and homeâ€based infusion therapy among haemophilic men. Haemophilia, 2014, 20, 340-348.	1.0	12
54	Characteristics of hemophilia patients with factor <scp>VIII</scp> inhibitors detected by prospective screening. American Journal of Hematology, 2015, 90, 871-876.	2.0	11

#	Article	IF	Citations
55	A Public Health Approach to the Prevention of Inhibitors in Hemophilia. American Journal of Preventive Medicine, 2014, 47, 669-673.	1.6	10
56	Measuring the quality of haemophilia care across different settings: a set of performance indicators derived from demographics data. Haemophilia, 2017, 23, e1-e7.	1.0	10
57	Evidence for the continued transmission of parvovirus <scp>B</scp>19 in patients with bleeding disorders treated with plasmaâ€derived factor concentrates. Transfusion, 2013, 53, 1143-1144.	0.8	8
58	Prophylaxis use among males with haemophilia B in the United States. Haemophilia, 2017, 23, 910-917.	1.0	8
59	Origins and organization of the NHLBI State of the Science Workshop: Generating a national blueprint for future research on factor VIII inhibitors. Haemophilia, 2019, 25, 575-580.	1.0	6
60	Risk factors associated with invasive orthopaedic interventions in males with haemophilia enrolled in the Universal Data Collection program from 2000 to 2010. Haemophilia, 2018, 24, 964-970.	1.0	5
61	Global Hemophilia Care: Data for Action. Annals of Internal Medicine, 2019, 171, 585.	2.0	5
62	Linking the world with training and research for improving haemophilia care. Haemophilia, 2008, 14, 43-48.	1.0	4
63	Characteristics, complications, and sites of bleeding among infants and toddlers less than 2 years of age with VWD. Blood Advances, 2021, 5, 2079-2086.	2.5	4
64	Hemophilia without prophylaxis: Assessment of joint range of motion and factor activity. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1035-1045.	1.0	3
65	The national haemophilia program standards, evaluation and oversight systems in the United States of America. Blood Transfusion, 2014, 12 Suppl 3, e542-8.	0.3	3
66	Occurrence rates of inherited bleeding disorders other than haemophilia and von Willebrand disease among people receiving care in specialized treatment centres in the United States. Haemophilia, 2022, 28, .	1.0	3
67	Cluster of inhibitors among adult inpatients with haemophilia in a single institution. Haemophilia, 2015, 21, e325-e328.	1.0	0